Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Intuniv

Shire gets US FDA approval for Intuniv, the first selective alpha-2A adrenergic receptor agonist for the treatment of ADHD

Shire has received US Food and Drug Administration (FDA) approval for Intuniv extended release tablets for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years.

Intuniv, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD. Although the mechanism of action is unknown, Intuniv is thought to directly engage receptors found in the prefrontal cortex. Stimulation of the postsynaptic alpha-2A receptors is thought to strengthen the working memory, reduce susceptibility to distraction, improve attention regulation, improve behavioural inhibition and enhance impulse control.

The efficacy of Intuniv in the treatment of ADHD was established in two similarly designed, placebo-controlled clinical trials in children and adolescents aged 6 to 17 years who met Diagnostic and Statistical Manual of Mental Disorders-IV criteria for ADHD. Investigators, parents and teachers reported statistically significant improvements with Intuniv.

Once-daily Intuniv is forecast to be available in US pharmacies in November and will come in four dosage strengths (1mg, 2mg, 3mg and 4mg). It will be marketed in the States by the Shire ADHD team.

3rd September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics